A carregar...
Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
We determined whether the approved myelofibrosis drug ruxolitinib (Jakafi(®)), an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could be repurposed as an anti-cancer agent for solid tumors. Ruxolitinib synergistically interacted with dual ERBB1/2/4 inhibitors to kill breast as well as lung, ovaria...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4904019/ https://ncbi.nlm.nih.gov/pubmed/27379204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2016.00142 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|